Granules India Limited is a large-scale, vertically integrated pharmaceutical company specializing in APIs, PFIs, and Finished Dosages with a focus on off-patent drugs.

Recent strategic developments include the acquisition of Senn Chemicals AG to expand into the high-value peptide CDMO segment, enhancing the company's global reach and technological capabilities.

The company reported significant revenue growth of 34% YoY in Q2 FY26, primarily driven by its formulations business in North America and Europe.

Granules continues to demonstrate robust R&D capabilities with 91 US FDA approvals to date, highlighting its commitment to innovation and regulatory compliance.

Operational excellence is evident as the company achieved a gross margin improvement and navigated multiple regulatory milestones, addressing FDA concerns successfully at their facilities.